Literature DB >> 8186889

FU-3 monoclonal antibody: a specific marker for malignant fibrous histiocytoma? An analysis of 32 malignant soft tissue and bone sarcomas.

M J Perez-Bacete1, A Llombart-Bosch.   

Abstract

An immunohistochemical study on frozen sections was carried out on 51 malignant tumours of soft tissue and bone using the FU-3 monoclonal antibody. This antibody is claimed to be specific for malignant fibrous histiocytoma (MFH) and liposarcoma and for normal and tumour cells located in perivascular fields. The results show a lack of specificity in MFH staining: several malignant tumours such as synovial sarcoma, fibrosarcoma, rhabdomyosarcoma, osteogenic sarcoma, and including an anaplastic malignant melanoma, presented positive staining somewhat similar to that found in MFH. The value of this antibody in the differential diagnosis of MFH is doubtful. It might be useful to recognize a common pathway of terminal differentiation expressed by several pleomorphic sarcomatous neoplasms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186889     DOI: 10.1007/bf00194607

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

1.  Malignant fibrous histiocytoma. Evidence of perivascular mesenchymal cell origin immunocytochemical studies with monoclonal anti-MFH antibodies.

Authors:  H Iwasaki; T Isayama; H Johzaki; M Kikuchi
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

2.  Malignant fibrous histiocytoma. Expression of monocyte/macrophage differentiation antigens detected with monoclonal antibodies.

Authors:  J A Strauchen; A Dimitriu-Bona
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

3.  Malignant fibrous histiocytoma. Nonspecific morphologic pattern, specific pathologic entity, or both?

Authors:  L P Dehner
Journal:  Arch Pathol Lab Med       Date:  1988-03       Impact factor: 5.534

4.  Sequential use of the PAP and immunogold staining method for the light microscopical double staining of tissue antigens.

Authors:  J Gu; J de Mey; M Moeremans; J M Polak
Journal:  Regul Pept       Date:  1981-03

5.  Malignant fibrous histiocytoma tumor cells resemble fibroblasts.

Authors:  G S Wood; J H Beckstead; R R Turner; M R Hendrickson; R L Kempson; R A Warnke
Journal:  Am J Surg Pathol       Date:  1986-05       Impact factor: 6.394

6.  Malignant fibrous histiocytoma. Proliferative compartment and heterogeneity of "histiocytic" cells.

Authors:  H Iwasaki; K Yoshitake; Y Ohjimi; M Kikuchi; T Isayama; S Yoh; N Shinohara; M Enjoji
Journal:  Am J Surg Pathol       Date:  1992-08       Impact factor: 6.394

Review 7.  Antibodies to intermediate filament proteins in the diagnosis and classification of human tumors.

Authors:  M Miettinen; V P Lehto; I Virtanen
Journal:  Ultrastruct Pathol       Date:  1984       Impact factor: 1.094

8.  Malignant fibrous histiocytoma. A tumor of facultative histiocytes showing mesenchymal differentiation in cultured cell lines.

Authors:  H Iwasaki; T Isayama; Y Ohjimi; M Kikuchi; S Yoh; N Shinohara; K Yoshitake; M Ishiguro; N Kamada; M Enjoji
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

9.  Characterization of human soft tissue sarcomas in nude mice. Evidence for histogenic properties of malignant fibrous histiocytomas.

Authors:  P J Roholl; D H Rutgers; L H Rademakers; R A De Weger; J R Elbers; J A Van Unnik
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

10.  Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma.

Authors:  C D Fletcher
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

View more
  1 in total

1.  Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.

Authors:  T Ueda; N Araki; M Mano; A Myoui; S Joyama; S Ishiguro; H Yamamura; K Takahashi; I Kudawara; H Yoshikawa
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.